Accord Animal Health Launches New Dexmedetomidine Option In UK With Focus On Affordability
2 days ago 
100 views
Accord Animal Health has launched Dexmedocord® (dexmedetomidine 0.5 mg/ml solution for injection for dogs and cats) in the UK, providing veterinary practices with a new competitively priced dexmedetomidine option supported by commercial rebates and available through all major UK veterinary wholesalers.
Dexmedocord® is indicated in cats and dogs for non-invasive, mildly to moderately painful procedures and examinations requiring restraint, sedation and analgesia. In dogs, it is also indicated for deep sedation and analgesia in concomitant use with butorphanol for medical and minor surgical procedures, and as a premedication in dogs and cats before induction and maintenance of general anaesthesia. Dexmedetomidine is the active dextrorotatory enantiomer of medetomidine and is widely used in small animal practice as part of sedation and anaesthesia protocols.
The launch forms part of Accord Animal Health’s wider commitment to improving access to high-quality veterinary medicines while supporting practices facing increasing commercial pressures. With costs continuing to rise across the sector, the company believes that competitively priced, clinically proven options have a vital role to play in helping practices maintain the standard of care their patients need.
“Veterinary practices need trusted products backed by accessible pricing and reliable supply,” said Bob Ferguson, Director of Animal Health at Accord Animal Health. “Dexmedocord® marks an important milestone as our first POM-V pharmaceutical launch in the UK and reflects the established expertise and strong heritage in high-quality pharmaceuticals that we bring through the wider Accord group. As we continue to grow our animal health portfolio, our aim is to support UK practices with solutions that reflect the needs of the veterinary profession.”
Dexmedocord® is the first in a planned series of POM-V launches from Accord Animal Health. Alongside veterinary medicines, the company portfolio also includes a range of nutraceutical products.
Dexmedocord® is available now through UK veterinary wholesalers. Veterinary professionals interested in discussing pricing and commercial terms can contact Key Account Manager, Gemma Young at[email protected].
For more information about Dexmedocord® and to explore the full Accord Animal Health product portfolio, visit accordanimalhealth.com.
More from Companion Consultancy
- Beaphar refreshes non-brushing dental range for cats and dogs
- The Moores Orthopaedic Clinic treats their 2000th patient
- BreathEazy highlights importance of species-specific spacer choice in equine inhalation therapy
- Krka expands NSAID portfolio with launch of Robexera® injectable
- AHPR reinforces leadership role in legislative reform following Defra consultation on VSA
2 days ago